lamivudinezidovudine sold brand name combivir among others fixeddose combination antiretroviral medication used treat contains two antiretroviral medications lamivudine used together taken mouth twice common side effects include headache feeling tired nausea diarrhea severe side effects may include bone marrow suppression muscle damage worsening hepatitis b previously infected high blood lactate liver may part recommended treatment medications nucleoside reverse transcriptase inhibitor nrti work blocking action enzyme reverse transcriptase virus requires lamivudinezidovudine approved medical use united states european union world health organizations list essential available generic indicated use combination additional antiretroviral agent treatment human immunodeficiency virus type lamividinezidovudine categorized pregnancy category c united states meaning potential risks baby pregnancy potential benefits may outweigh data supports safety combination pregnancy often preferred fixed dose combinations common adverse effects lamividinezidovudine similar nrtis includes headache neutropenia anemia nausea vomiting myopathy nail serious potentially lifethreatening adverse effects reported include lactic acidosis hepatic steatosis rare adverse event mostly associated hivpositive patients chronic hepatitis b virus hbv infections risk potential flares hepatitis occur abrupt discontinuation lamividinezidovudine lamivudine also used low doses treatment active lamividinezidovudine interacts stavudine zalcitabine competing intracellularly activation results inhibiting also known interaction nephrotoxic bone marrow suppressive agents eg doxorubicin increases risk hematologic toxicity monitoring renal function hematologic tests used assess potential half lives lamivudine zidovudine affected food absorption rates slowed taken food clinically significant therefore lamivudinezidovudine may taken without combination lamivudine zidovudine composed two nucleotide reverse transcriptase inhibitors lamivudine zidovudine competitively inhibit reduce activity reverse transcriptase rt causing hiv infected cells decrease number viruses lamivudine zidovudine act nucleoside analogs substrates human nucleoside kinases initial phosphorylation step crucial drugs activity converted active triphosphate form host kinases drug incorporated end growing chain viral dna causing chain terminated nucleotides longer added growing viral dnacitation needed lamividuine zidovudine combination therapy believed work synergistically together prevent mutations hiv virus contribute drug lamivudine well absorbed body distributes widely extravascular space oral bioavailability overall metabolism insignificant approximately drug found unchanged urine known metabolite found humans transsulfoxide halflife lamivudine hours binds poorly plasma zidovudine also well absorbed body penetrates cerebrospinal fluid oral bioavailability primarily metabolized liver glucuronidation primary metabolite gzdv inactive metabolite produced first pass metabolism halflife zidovudine hours binds poorly plasma lamivudine zidovudine extensively metabolized liver enzymescitation needed lamivudinezidovudine brand name combivir introduced market fda approval impact history significant first combination therapy fixed dose hivpositive people soon solidified title gold standard prescribed nrti initial hiv treatment newly diagnosed patients arrival combivir seen new revolution hiv therapy improved toxicity profile tolerability especially compared undesirable side effects lone azt therapy unfavorable facial lipoatrophy seen stavudine monotherapy lamivudinezidovudine world health organizations list essential drug formulations tablets mouth httpsenwikipediaorgwikilamivudinezidovudine